Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511643 | 1.00 | GPR119 (0.48) | GPR119NR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL15511715 | 1.00 | GPR119 (0.48) | GPR119NR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL13735774 | 0.85 | GPR119 (0.32) | GPR119 | |
| SCHEMBL15512294 | 0.83 | NR1H2 (0.53) | GPR119NR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL15511656 | 0.83 | NR1H2 (0.53) | GPR119NR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL15511654 | 0.83 | NR1H2 (0.53) | GPR119NR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL15511942 | 0.82 | GPR119 (0.44) | GPR119NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL13734501 | 0.82 | GPR119 (0.44) | GPR119NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL5416595 | 0.82 | GPR119 (0.41) | GPR119NR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL613606 | 0.80 | GPR119 (0.47) | GPR119NR1H2MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | GPR119 1/4885NR1H2 507/4885MEN1 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.